(Boc-2-aminoethyl)naproxen | 646511-11-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (Boc-2-aminoethyl)naproxen
• 英文别名: 2-((tert-Butoxy)carbonylamino)ethyl (2S)-2-(6-methoxy(2-naphthyl))propanoate；2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
• CAS: 646511-11-7
• 化学式: C₂₁H₂₇NO₅
• 分子量: 373.449
• InChiKey: VUJLKAMEUUHAGR-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (Boc-2-aminoethyl)naproxen 在 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]ethyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
  参考文献：
  名称：

  荧光标记的环氧合酶-2抑制剂对癌症中环氧合酶-2过表达的成像：合成和生物学研究

  摘要：

  通过将抗炎药布洛芬，（S）-萘普生和塞来昔布与7-硝基苯并呋喃山（NBD）荧光团连接，合成了一组特定于环氧合酶2（COX-2）的荧光癌生物标记。体外COX-1 / COX-2抑制的研究表明，所有这些荧光缀合物的是COX-2抑制剂（IC 50范围：0.19-23.0μ中号）与可感知的COX-2选择性指数（SI≥4.3-444）。在这项研究中，塞来昔布-NBD共轭N-（2-（（7-硝基苯并[ c ] [1,2,5]恶二唑-4-基）氨基）乙基）-4-（5-（对甲苯基）- 3-（三氟甲基）-1 H-吡唑-1-基）苯磺酰胺（14），其显示的最高COX-2抑制的效力和选择性（COX-2的IC 50 = 0.19μ中号;使用COX-SI = 443.6），被认定为即将发生的COX-2特异性的生物标记用于癌症的荧光成像2表达人类结肠癌细胞系（HCA-7）。

  DOI：

  10.1002/cmdc.201300355
• 作为产物：
  描述：

  N-(叔丁氧羰基)乙醇胺 、 萘普生 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (Boc-2-aminoethyl)naproxen
  参考文献：
  名称：

  荧光标记的环氧合酶-2抑制剂对癌症中环氧合酶-2过表达的成像：合成和生物学研究

  摘要：

  通过将抗炎药布洛芬，（S）-萘普生和塞来昔布与7-硝基苯并呋喃山（NBD）荧光团连接，合成了一组特定于环氧合酶2（COX-2）的荧光癌生物标记。体外COX-1 / COX-2抑制的研究表明，所有这些荧光缀合物的是COX-2抑制剂（IC 50范围：0.19-23.0μ中号）与可感知的COX-2选择性指数（SI≥4.3-444）。在这项研究中，塞来昔布-NBD共轭N-（2-（（7-硝基苯并[ c ] [1,2,5]恶二唑-4-基）氨基）乙基）-4-（5-（对甲苯基）- 3-（三氟甲基）-1 H-吡唑-1-基）苯磺酰胺（14），其显示的最高COX-2抑制的效力和选择性（COX-2的IC 50 = 0.19μ中号;使用COX-SI = 443.6），被认定为即将发生的COX-2特异性的生物标记用于癌症的荧光成像2表达人类结肠癌细胞系（HCA-7）。

  DOI：

  10.1002/cmdc.201300355

文献信息

• Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
  申请人：NitroMed, Inc.

  公开号：US20040024057A1

  公开（公告）日：2004-02-05

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝化非甾体抗炎药（NSAIDs）及其药用盐，以及包含至少一种亚硝化NSAID的新型组合物，以及可选地，至少一种提供、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种亚硝化NSAID和至少一种提供、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种亚硝化NSAID，可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
  申请人：Earl A. Richard

  公开号：US20050222243A1

  公开（公告）日：2005-10-06

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  本发明描述了新型亚硝基化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，以及包含至少一种亚硝基化NSAID和可选地至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性的内皮源性舒张因子水平或是一氧化氮合酶的底物，和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝基化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性的内皮源性舒张因子水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝基化NSAID、可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。本发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093671A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝酰化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，并且描述了至少包含一种亚硝酰化NSAID和可选的至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性内皮源性松弛因子的水平或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性内皮源性松弛因子的水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID，可选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防使用非甾体抗炎化合物导致的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use
  申请人：Earl Richard

  公开号：US20110098253A1

  公开（公告）日：2011-04-28

  The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

  该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防非甾体类抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的新组合物的给药方法，该组合物包括至少一种硝化的非甾体类抗炎药，以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂。
• TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER
  申请人：SEIKAGAKU CORPORATION

  公开号：US20220370630A1

  公开（公告）日：2022-11-24

  As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.

  提供了一种跨黏膜递送系统，包括含有药物活性成分的疏水化合物和软骨素硫酸盐的共轭物，能够有效地将药物活性成分递送到膀胱的黏膜下组织。